Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LoneStar Heart Inc.

Addressing heart failure with an injectable biopolymer

This article was originally published in Start Up

Executive Summary

LoneStar Heart's injectable biopolymer Algisyl-LVR represents a new advanced HF treatment strategy based on a medically accepted principle that a reduction in muscle tension and wall stress of the dilated heart will improve its function. The company, which originally envisioned Algisyl-LVR as a carrier for targeted delivery of biologics, drugs, or stem cells, discovered in animal studies that use of the biopolymer by itself had a profound effect on improving the mechanics of the heart.

You may also be interested in...



ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.

ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.

ASCO 2023 – Pfizer Pushes Forward In Drug-Resistant Breast Cancer

While Ibrance has been bested by class rivals Pfizer is working on projects that might overcome CDK4/6 inhibitor resistance, although it is not alone.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037900

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel